JINGXIN (002020.SZ): files for listing on HKEX: CNS/CVD Pharma Group
- Dimdazenil (Junoenil®) is the Company's sole approved innovative drug, approved in China in 2023 for insomnia, and its pipeline includes JX2201, a Class 1 innovative drug candidate for elevated lipoprotein(a) levels.
- Revenue is derived from three segments — drugs (generic drugs, innovative drugs, TCM and biologics), APIs and medical equipment — with drug sales accounting for the majority.
- As of June 30, 2026, its manufacturing facilities for products had an aggregate GFA of approximately 409,357 sq.m.; the Company operates ten production facilities in the PRC and one medical equipment facility in South Korea.
NewTimeSpace News: On 18 September 2026, Zhejiang Jingxin Pharmaceutical Co., Ltd. (002020.SZ) filed an application for listing on the Main Board of the Stock Exchange of Hong Kong Limited and published its Application Proof on the exchange's website, with CITIC Securities as sole sponsor. The Company is a pharmaceutical group strategically focused on two core therapeutic areas: (i) central nervous system (CNS) disorders and (ii) cardiovascular and cerebrovascular diseases.
The Company's revenue is mainly generated from the sales of marketed products, covering (i) drugs (including generic drugs, innovative drugs, TCM and biologics); (ii) APIs; and (iii) medical equipment, with drug sales accounting for the majority of revenue during the Track Record Period. As of the Latest Practicable Date, Dimdazenil (Junoenil®) is the Company's sole approved innovative drug, which was approved in China in 2023 for the treatment of insomnia. The Company is also advancing selected drug candidates in its focus therapeutic areas, including JX2201, a Class 1 innovative drug candidate for the treatment of elevated lipoprotein(a) levels.
In 2025, the Company's total revenue was RMB 4,069.4 million, net profit was RMB 771.7 million and R&D investment was RMB 368.0 million. As of June 30, 2026, its manufacturing facilities for products occupied an aggregate site area of approximately 1,214,117 sq.m. and had an aggregate GFA of approximately 409,357 sq.m. As of the Latest Practicable Date, the Company operated ten manufacturing facilities in the PRC, covering all of its product categories, and one manufacturing facility in South Korea for medical equipment.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- JINGXIN HKEX IPO Filing Lapses; 2024 Revenue of RMB 4.16 Billion and Net Profit of RMB 719 Million
- HK Stock Connect Weekly: HSI Falls 0.22% for the Week, RMB Counters Proposed for Inclusion in Stock Connect, HQVT Surges Over 70%
- HK Recently Listed Stocks Weekly: HQVT Surges 95.59%, Z.AI Tops Liquidity at HK$8.30 Billion Average Daily Turnover-20260918
- Weekly Hong Kong ETF Average Returns by Manager (Third Week of September 2026)
- Weekly Hong Kong ETF Returns Statistics (Third Week of September 2026)
